CVR number 19991741
Industry 86.9090 Other human health activities

MK 97 ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  0.8% 0.8% 0.8% 0.8% 0.8%  
Bankruptcy risk  13.8% 9.1% 9.8% 16.9% 17.3%  
Credit score (0-100)  17 27 24 9 8  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  194 239 239 330 376  
EBITDA  77.6 -40.8 -36.5 20.0 15.4  
EBIT  64.1 -54.2 -40.2 15.1 7.1  
Pre-tax profit (PTP)  61.7 -54.6 -40.5 15.0 7.0  
Net earnings  98.2 -42.6 -89.0 15.0 7.0  
Pre-tax profit without non-rec. items  61.7 -54.6 -40.5 15.0 7.0  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  17.1 3.7 0.0 20.1 11.8  
Shareholders equity total  85.4 42.8 -46.2 -31.1 -24.1  
Interest-bearing liabilities  0.0 2.2 2.2 27.2 27.9  
Balance sheet total (assets)  160 166 45.2 50.0 38.7  
Net Debt  -93.3 -105 -40.5 -2.6 1.0  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  194 239 239 330 376  
Gross profit growth  1,846.2% 22.9% -0.1% 38.2% 14.2%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  160 166 45 50 39  
Balance sheet change%  93.8% 3.7% -72.7% 10.5% -22.5%  
Added value  77.6 -40.8 -36.5 18.8 15.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -27 -27 -7 15 -17  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 -2.0 1.0 2.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  33.0% -22.7% -16.8% 4.6% 1.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  50.3% -33.3% -31.2% 17.5% 10.0%  
ROI %  150.2% -83.1% -170.0% 102.6% 26.0%  
ROE %  116.9% -66.4% -202.1% 31.6% 15.8%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  53.4% 25.8% -50.5% -38.4% -38.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -120.3% 258.1% 110.9% -13.1% 6.6%  
Gearing %  0.0% 5.2% -4.8% -87.4% -115.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 34.2% 15.0% 0.6% 0.6%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  1.9 1.3 0.5 0.4 0.4  
Current Ratio  1.9 1.3 0.5 0.4 0.4  
Cash and cash equivalent  93.3 107.5 42.7 29.9 26.9  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  68.3 39.1 -46.2 -51.3 -35.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  78 -41 -36 19 15  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  78 -41 -36 20 15  
EBIT / employee  64 -54 -40 15 7  
Net earnings / employee  98 -43 -89 15 7